You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

  1. Dynamic Frequency Passive Millimeter-Wave Radiometer Based on Optical Up-Conversion

    SBC: PHASE SENSITIVE INNOVATIONS INC            Topic: 941D

    In the proposed effort, we will leverage this extensive experience and capabilities to realize a frequency agile mmW radiometer that can cover the range of DC-110 GHz and can be scaled to DC-200 GHz under Phase II. Ours is a photonic system that multiplies and up-coverts a low-frequency reference signal onto an optical carrier (laser) using EO modulation, then uses the modulation sidebands to inj ...

    SBIR Phase I 2013 Department of CommerceNational Oceanic and Atmospheric Administration
  2. Creating Spatial Disorientation in Flight Simulation

    SBC: CONTINUUM DYNAMICS INC            Topic: 122FA1

    Training in the symptoms of Spatial Disorientation (SD) has shown to be valuable in aiding pilots to recognize its onset and provide a means for mitigating its effects, but such demonstrations have traditionally been associated with specialized equipment and devices. Since the vast majority of pilots for the commercial aviation jet fleet are trained (or recertified) on 6-degree-of-freedom (DOF) h ...

    SBIR Phase I 2013 Department of Transportation
  3. Development of the Novel Small molecule drug Posiphen to treat Traumatic Brain In

    SBC: DIAMIR, LLC            Topic: NIA

    DESCRIPTION (provided by applicant): Alzheimer's Disease (AD) is the most common neurodegenerative disease: 5.4 million people are currently living with AD in the US, and up to 80 million Americans (over 55 years old) are considered to constitute the riskgroup for AD. In 2011, the annual cost of healthcare services for AD patients in the US reached 183 billion. There are currently no disease ...

    SBIR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health
  4. Coronary Post-Dilatation Catheter

    SBC: P2D, INC            Topic: NIA

    DESCRIPTION (provided by applicant): The goal of this proposal is to develop tumor necrosis factor (TNF )-inhibiting compounds as neuroprotectant drugs for treating Alzheimer's disease (AD). Current FDA-approved AD interventions are symptomatic treatments with limited efficacy which do not affect AD etiology or modify the course of disease progression. Thus, a critical need exists for a nov ...

    SBIR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health
  5. Administrative supplement to 5R44DA025375-03: Prescription drug abuse prevention

    SBC: WELLGEN, INC.            Topic: NCCAM

    DESCRIPTION (provided by applicant): Type 2 Diabetes (T2D) is an inflammatory disease affecting 26 million people in the US (11%) and is predicted to affect more than 30% of adults in the US by 2050. The economic cost of T2D is over 200 billion a year. People with T2D suffer from hyperglycemia due to low insulin production, poor transport of insulin, or cellular resistance to insulin which can l ...

    SBIR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health
  6. NIH Phase II-UNCD as Bio-Inert Interface for Anti-Thrombogenicity Applications in

    SBC: Lucidicor Inc.            Topic: NCI

    DESCRIPTION: Protein kinases are chemically tractable drug targets, yet less than 5% of the human kinome has been thoroughly explored with selective small molecule inhibitors to demonstrate their therapeutic utility. Pharmaceutical companies are interested in evaluation of the therapeutic potential of targeting kinases to define new opportunities to address unmet medical needs. Lucidicor, Inc. h ...

    SBIR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health
  7. Novel Antithrombotic Diadenosine Tetraphosphate Analogs

    SBC: IMMUNOMEDICS, INC.            Topic: NCI

    DESCRIPTION (provided by applicant): The overall goal of this SBIR application is to initiate a clinical trial with a bispecific antibody (bsMAb) pretargeting procedure for detecting pancreatic carcinoma, based on a highly specific antibody (PAM4) recognizing an epitope found in pancreatic mucin. The pretargeting procedure has been shown pre-clinically and clinically to be highly sensitive and mo ...

    SBIR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health
  8. CBT Supervisor's Toolkit: Phase II

    SBC: IMMUNOMEDICS, INC.            Topic: NCI

    DESCRIPTION (provided by applicant): Triple-negative breast cancer (TNBC) is a subset of breast cancers with poor prognosis and high mortality due to the lack of effective therapeutic regimens. This Phase I SBIR application is to develop E1-Rap, a novel immunoRNases, for treating TNBC. E1-Rap is a DOCK-AND-LOCKTM (DNLTM) complex, comprising four copies of ranpirnase (Rap) site-specifically tethere ...

    SBIR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health
  9. A Promotora Program to Prevent Primary Tooth Decay in Low-income Latino Children

    SBC: THERMALIN DIABETES, INC.            Topic: NIDDK

    DESCRIPTION (provided by applicant): We seek to develop a rapid-acting U-500 insulin analog formulation for patients with Type 2 and Type 1 diabetes mellitus (T2DM and T1DM). Such a novel product would improve treatment in two contexts: (i) for T2DM patients with marked insulin resistance (as associated with diabesity, secondary to corticosteroid treatment, the mitochondrial diabetes syndrome MI ...

    SBIR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health
  10. Smart Capsule for Automatic Adherence Monitoring

    SBC: THERMALIN DIABETES, INC.            Topic: NIDDK

    DESCRIPTION (provided by applicant): Close-loop systems of insulin delivery-comprising an insulin pump, continuous glucose monitor, and feedback-based control algorithm-provide a promising technology to enable tight glycemic control in Type 1 diabetes mellitus with improved patient convenience and compliance. The safety and efficacy of such coupled devices (also known as an artificial pancreas ) ...

    SBIR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government